The prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that was initially thought to be specific to the prostate but was subsequently found to be expressed in tumor-associated neovascularization in many cancer types, such as ccRCC [6, 7], glioma [8, 9], thyroid cancer [10], breast cancer [11], primary cholangiocarcinoma [12], and more. The gene discussed is FOLH1; the disease is neoplasm.